Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02166437|
Recruitment Status : Unknown
Verified October 2016 by Toshihiko Kono, Tomidahama Hospital.
Recruitment status was: Recruiting
First Posted : June 18, 2014
Last Update Posted : October 19, 2016
|Condition or disease|
Registry criteria: Patients treated in the investigators hospital using teriparatide. Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (< young adult mean 65%).
Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds participants
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study|
|Study Start Date :||November 2013|
|Estimated Primary Completion Date :||November 2017|
|Estimated Study Completion Date :||November 2018|
Patients treated with alendronate
Patients treated with minodronate
Patients treated with denosmab
- Clinical results of bisphosphonate vs. denosmab following daily teriparatide treatment [ Time Frame: Up to 36 months ]
The investigators plan to analyze 500 patients who treated with bisphosphonate or denosmab following daily teriparatide treatment.
We investigate changes in BMD and bone turnover markers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02166437
|Contact: Rui Niimi, MD, PhD||(81)-email@example.com|
|Yokkaichi, Mie, Japan, 510-8008|
|Contact: Rui Niimi, MD, PhD (81)-59-365-0023 firstname.lastname@example.org|
|Principal Investigator: Rui Niimi, MD, PhD|
|Study Director:||Rui Niimi, MD, PhD||Tomidahama Hospital|